Charles R. Eyler is SEE REMARKS at PUMA BIOTECHNOLOGY, INC. (PBYI). They have made 6 open-market trades across 1 company since 2017, most recently 2019-02-04.
CIK 0001358246
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PBYI | 31,957 | $314K |
Shares reported on the most recent Form 4, priced at the 2019-02-06 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PBYI | SELL | 2019-02-04 | 2019-02-06 | $27.64 | $2K | -2.6% | +38.2% | +10.2% |
| PBYI | SELL · 10b5-1 | 2019-01-22 | 2019-01-24 | $24.80 | $18K | +5.4% | +10.0% | +31.0% |
| PBYI | SELL | 2019-01-03 | 2019-01-04 | $20.67 | $25K | +16.3% | +27.3% | +57.9% |
| PBYI | SELL · 10b5-1 | 2018-12-03 | 2018-12-04 | $22.77 | $28K | -7.3% | -10.1% | +73.4% |
| PBYI | SELL · 10b5-1 | 2018-07-20 | 2018-07-24 | $51.95 | $32K | -5.5% | -18.0% | -20.7% |
| PBYI | SELL | 2018-06-01 | 2018-06-04 | $53.00 | $64K | +11.5% | +21.1% | -7.4% |
| PBYI | SELL | 2018-01-22 | 2018-01-24 | $92.85 | $124K | -8.8% | -8.7% | -24.7% |
| PBYI | SELL | 2017-12-01 | 2017-12-05 | $105.46 | $279K | +5.4% | +2.7% | -18.1% |
| PBYI | SELL | 2017-07-20 | 2017-07-24 | $95.15 | $126K | -10.5% | -13.9% | +28.0% |
| PBYI | SELL · 10b5-1 | 2017-01-20 | 2017-01-24 | $33.24 | $27K | +1.2% | +5.3% | +13.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.